ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1209

Sporadic Hemophagocytic Lymphohistiocytosis (sHLH): A Polygenic Disease? a Report of French National,  Prospective, Cohort of 205 Patients

Coralie Bloch-Queyrat1,2, Jean Philippe Jais3, Marine Gil4, Brigitte Bader-Meunier5, Olivier Hermine6,7 and Genevieve de Saint-Basile4, 1Clinical Research Unit, University Hospital Paris Seine Saint Denis, AP-HP, Bobigny, France, 2Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications INSERM U 1163 / CNRS ERL 8254 Institut IMAGINE, Paris, paris, France, 3Biostatstical Departement, Department of biostatistics Necker Enfants Malades Hospital, AP-HP, Paris, France, 4Normal and pathological homeostasis of the immune system laboratory Institut IMAGINE Paris, Paris, France, 5Pediatric Rheumatology & Immunology, Pediatric Rheumatology & Immunology, Necker hospital, Imagine Institution, Paris, France, 6Department of Hematology, Hôpital Necker, Paris, France, 7Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications INSERM U 1163 / CNRS ERL 8254 Labex on Red cell and iron metabolism Institut IMAGINE, Paris, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Clinical research, Genetic disorders, immune activation, immune deficiency and macrophage activation syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Genetics, Genomics and Proteomics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The role of genetic factors in the occurrence and/or severity of sHLH is not yet known. Therefore, from 2010 to 2016, we performed a national, prospective, cohort study to analysis HLH-associated genes (Lyst, perforine, Munc 13-4, syntaxine-11, STXBP-2, SH2D1, XIAP, Rab-27, Itk) in sHLH.

Methods: We included 190 adults and 15 children fulfilling adapted Histiocyte Society criteria. Data collected included: (i) clinical and biological features, (ii) malignant, autoimmune or infectious associated diseases, (iii) treatment and evolution at M0 and M12. HLH associated-genes could be sequenced in 185 patients and analyzed in 147. Mutational profiles of Non Synonymous (NS), rare variants (frequency < 1% or 5% in reference populations) were compared to control populations issued from the “1000 genomes” project and in house repositories.

Results: Heterozygous (n=111) and homozygous (n=2) rare variants were identified in 80 patients. For 26 patients, rare variants were localized in 2 or 3 genes. Compared with control populations, overall rare variants frequency didn’t differ significantly. However, rare variants (frequency < 1% or < 5%) affecting 2 or more genes in patients were significantly different from controls (p<0.0002 and p< 0.03). Combinations of rare variants were enriched with perforin and RAB27a or STXBP2 genes. sHLH were associated with hematologic malignancies and autoimmune diseases in 51 and 20 cases respectively, and idiopathic in 75 cases with infectious trigger in half of the cases. Severity of sHLH (relapsing cases, ICU transfer, or death) is significantly correlated with the presence of combination of rare variants (p=0,0043), especially in the groups of autoimmune diseases or idiopathic.

Conclusion: In conclusion, genes of primary HLH may also be involved in sHLH physiopathology and outcome.


Disclosure: C. Bloch-Queyrat, None; J. P. Jais, None; M. Gil, None; B. Bader-Meunier, None; O. Hermine, None; G. de Saint-Basile, None.

To cite this abstract in AMA style:

Bloch-Queyrat C, Jais JP, Gil M, Bader-Meunier B, Hermine O, de Saint-Basile G. Sporadic Hemophagocytic Lymphohistiocytosis (sHLH): A Polygenic Disease? a Report of French National,  Prospective, Cohort of 205 Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/sporadic-hemophagocytic-lymphohistiocytosis-shlh-a-polygenic-disease-a-report-of-french-national-prospective-cohort-of-205-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sporadic-hemophagocytic-lymphohistiocytosis-shlh-a-polygenic-disease-a-report-of-french-national-prospective-cohort-of-205-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology